Antibody Bioavailability Containment Protein 
The Pharma Data
APRIL 7, 2023
One of the greatest challenges in modern drug design is to find compounds that satisfy somewhat contradictory requirements – they need to be small enough to permeate human cell membranes, while being large enough to target various protein surfaces and protein–protein interactions.
Drug Discovery World
AUGUST 3, 2022
Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. These considerations limit their application as therapeutics.
Expert insights. Personalized for you.
40 
Let's personalize your content